NFKB1 and esophageal squamous cell carcinoma: Furthermore, MTS and transwell migration assays were conducted in the rhIL-1α-treated ESCC cells with an Erk inhibitor (PD98059) or NF-κB inhibitor (BAY11-7082) to evaluate the effect of inhibiting Erk or NF-κB in rhIL-1α-induced malignant phenotypes.